Silo Pharma Inc. is a pioneering biopharmaceutical company dedicated to innovating therapeutics by integrating traditional treatment approaches with psychedelic research, focusing on mental health disorders and rare diseases. Utilizing its proprietary drug delivery technologies and forming strategic alliances, Silo aims to ensure the responsible clinical application of psychedelics within a regulatory framework. With a promising pipeline of candidates addressing significant unmet medical needs, Silo Pharma is well-positioned to capitalize on the growing interest in mental health therapeutics, offering potential value creation for investors in this dynamic sector.
| Revenue (TTM) | 54,080 |
| Gross Profit (TTM) | -7,987 |
| EBITDA | $-4.45M |
| Operating Margin | -8250.00% |
| Return on Equity | -91.20% |
| Return on Assets | -44.30% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $5.24 |
| Price-to-Book | 0.71 |
| Price-to-Sales (TTM) | 71.11 |
| EV/Revenue | 6.38 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.25M |
| Float | $1.57M |
| % Insiders | 12.94% |
| % Institutions | 9.01% |
Volatility is currently contracting
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo's common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SILO and any ticker you trade — then tracks every position and per-strategy win rate.
